Clinical trials: Withdrawal Syndrome
Neonatal Opiate Withdrawal Syndrome
Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach
The overall objective is to determine if the ESC care approach will reduce the time until infants being managed for NOWS are medically ready for discharge.
- Trial name
- (ESC-NOW) (NCT04057820)
- Testing
- Finnegan Neonatal Abstinence Scoring Tool, Eat, Sleep, Console (ESC) care tool
- Where
- 26 sites in United States
- Volunteers
- 1,305 people
- Sponsor
- Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program
Intoxication, Delirium Tremens (DTs)
Preventox - a Digital Intervention for Patients With Intoxications in Intensive Care
Background and purpose At present, occasional referral to psychiatric or addiction services is the only aftercare option offered following an intoxication/overdose requiring intensive care.
- Conditions
- Intoxication, Delirium Tremens (DTs), Poisoning by Psychoactive Substances, Suicidal Attempt
- Trial name
- NCT07819500
- Testing
- Preventox, a digital self-help tool for patients with intoxications in intensive care., Preventox control group
- Volunteers
- 50 people
- Sponsor
- Karolinska Institutet
Withdrawal Symptoms
A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects
This single-center study is a randomized, double-blind, active-controlled, multiple-dose, parallel group study to evaluate the potential withdrawal effects, safety and tolerability, and pharmacokinetic and pharmacodynamic effects…
- Trial name
- NCT02391571
- Testing
- Oxycodone/Naltrexone Capsules, Oxycodone
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Elite Laboratories, Inc
Cardiomyopathy, Dilated
Clinical Observation of Long-term Cardiac Function Prognosis in Patients With PPCM Who Have Recovered Cardiac Function
Peripartum cardiomyopathy (PPCM) is an idiopathic cardiomyopathy that occurs in late pregnancy and early postnatal period, which is mainly characterized by varying degrees of impaired ventricular systolic function and symptoms…
- Trial name
- NCT06039072
- Testing
- Patients with cardiac function recovered for more than one year and discontinued were in the discontinuation group.
- Volunteers
- 120 people
- Sponsor
- Qilu Hospital of Shandong University
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment.
- Trial name
- CYPRESS (NCT05696717)
- Testing
- Ampreloxetine
- Where
- 79 sites in United States, Argentina and 18 more
- Volunteers
- 102 people
- Sponsor
- Theravance Biopharma
Cannabis Withdrawal
Effect of PP-01 on Cannabis Withdrawal Syndrome
This study will be a randomized, double-blind, placebo-controlled, multicenter trial conducted to evaluate whether PP-01 mitigates the withdrawal symptoms associated with discontinuing cannabis in participants with moderate to…
- Trial name
- NCT05494437
- Testing
- PP-01 High Dose, PP-01 Low Dose, Nabilone
- Where
- 18 sites in United States
- Volunteers
- 234 people
- Sponsor
- PleoPharma, Inc.
Alcohol Withdrawal Syndrome
Treatment of Alcohol Withdrawal in Hospital Patients
The purpose of this study is to test how tolerable and effective lorazepam is when used to treat alcohol withdrawal in hospital patients at risk for alcohol withdrawal.
- Trial name
- NCT00249366
- Testing
- Lorazepam (drug), Lorazepam
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- Virginia Commonwealth University
Neonatal Opioid Withdrawal, Neonatal Opioid Withdrawal Syndrome
Cerebral Physiology of NOWS
This study will use a new device to measure blood flow and oxygen levels in the brains of newborn infants who have had exposure to opioid medications in the womb, compared to newborns who have not had any exposure.
- Conditions
- Neonatal Opioid Withdrawal, Neonatal Opioid Withdrawal Syndrome, Opioid Use Disorder, Intrauterine Exposure
- Trial name
- NIRS for NOWS (NCT07610746)
- Testing
- FD-NIRS and DCS
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Indiana University
Fragile X Syndrome
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
There will be four study periods: Screening (up to 14 days in length), the Treatment Period (8 weeks), the Withdrawal Period (22 days), and Follow-up Period (up to 31 days).
- Trial name
- Harbor-C (NCT01325220)
- Testing
- arbaclofen
- Where
- 28 sites in United States
- Volunteers
- 172 people
- Sponsor
- Seaside Therapeutics, Inc.
Sepsis, ARDS, Human
Factors Associated With Decisions to Withhold or Withdraw Intensive Care
Medical and socioeconomic data are extracted from the Swedish Intensive Care Registry (SIR), the Swedish National Patient Registry and Statistics Sweden for all adult patients admitted to in Swedish intensive care units between…
- Conditions
- Sepsis, ARDS, Human, COVID-19
- Trial name
- NCT05394961
- Testing
- Treatment in an intensive care unit with a diagnosis of sepsis and/or ARDS and/or covid-19
- Where
- Sweden
- Volunteers
- 33,256 people
- Sponsor
- Uppsala University
Chronic Pain, Drug Dependence of Morphine Type
Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal
The proposed clinical trial will address the problem of opioid withdrawal. Opioids are essential for pain-relief in the short term, but their continued use is associated with a host of adverse effects.
- Conditions
- Chronic Pain, Drug Dependence of Morphine Type, Symptom, Withdrawal
- Trial name
- NCT04939623
- Testing
- Probenecid
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Calgary
Substance Withdrawal Syndrome
Validation of a Pediatric-Specific Abstinence Syndrome Assessment Tool
The purpose of this study is to assess the validity and reliability of an abstinence syndrome assessment tool used in pediatric patients with iatrogenic opioid dependence.
- Trial name
- NCT00792415
- Where
- United States
- Sponsor
- Banner Health
Sleep Apnea, Obstructive, Endothelial Dysfunction
Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal
Obstructive sleep apnea hypopnea syndrome (OSAS) is a frequent disease with neuropsychological and cardiovascular (CV) consequences.
- Trial name
- ORTAP (NCT05939934)
- Testing
- Mandibular advancement device treatment
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Angers
Chronic Pain, Opiate Withdrawal Syndrome
Treatment of Withdrawal Symptoms With NADA Acupuncture in Chronic Pain Patients
This project aims at examining the following hypotheses: Treatment with NADA and clonidine reduces intensity of withdrawal symptoms to a greater extent than treatment with clonidine.
- Trial name
- NCT03397212
- Testing
- NADA acupuncture
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Alcohol Withdrawal Syndrome
Effect of Clinical and Biochemical Variables Over Morbidity and Mortality in Alcohol Withdrawal Syndrome Patients
The goal of this observational study is to describe the impact measured through the Odds Ratio (OR) of different variables of clinical and biochemical alterations on the duration of the syndrome alcohol withdrawal patients…
- Trial name
- NCT06589973
- Testing
- Study Cohort
- Where
- Mexico
- Volunteers
- 195 people
- Sponsor
- Hospital General de Mexico
Withdrawal Syndrome
Protocolized Sedative Weaning VS. Usual Care in Pediatric Critically Ill, RCT
Sedative and analgesic agents are widely used in the ICU. These agents can provide hypnotic effect, pain alleviation, cooperation, and synchronizing ventilatory support.
- Trial name
- NCT03018977
- Testing
- The sedative weaning protocol group, The usual group
- Where
- Thailand
- Volunteers
- 60 people
- Sponsor
- Ramathibodi Hospital
Alcoholism
Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU
Background: Alcohol is the leading psychoactive substance consumed in France, with about 15 million regular consumers. The National institute on Alcohol Abuse and Alcoholism (NIAAA) considers alcohol abuse to be more than 14…
- Trial name
- BACLOREA (NCT02723383)
- Testing
- BACLOFEN
- Where
- 18 sites in France
- Volunteers
- 314 people
- Sponsor
- Nantes University Hospital
Substance Withdrawal Syndrome
EA for PAAS: A pRCT
In 2019, around 27 million people worldwide, corresponding to 0.5% of the adult population, have used amphetamine-type stimulants (ATS). More than one-third of these 27 million users of ATS were in East and South-East Asia.
- Trial name
- NCT04917185
- Testing
- Electro-Acupuncture
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Chengdu University of Traditional Chinese Medicine
Opioid Withdrawal (Disorder)
Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal
Stopping prescription opioid pain medications can be difficult due to withdrawal symptoms. This study will test if LUCEMYRA helps reduce withdrawal symptoms and helps more people reduce their opioid dose compared to placebo.
- Trial name
- TAPER (NCT04070157)
- Testing
- Lofexidine
- Where
- 12 sites in United States
- Volunteers
- 4 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Substance Withdrawal Syndrome, Opiate Addiction
Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction
The purpose of this study is to evaluate the relative exposures of lofexidine and its major metabolites in subjects seeking buprenorphine dose reduction.
- Conditions
- Substance Withdrawal Syndrome, Opiate Addiction, Opiate Dependence
- Trial name
- NCT02801357
- Testing
- lofexidine administration in subjects seeking buprenorphine dose reduction
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- USWM, LLC (dba US WorldMeds)